The undoubted benefits of therapeutic corticosteroids carry a high price in side effects. Prominent among these is extensive loss of trabecular bone with widespread structural collapse. As in practice the good and the bad effects cannot be separated, the prevention and treatment of iatrogenic corticosteroid osteoporosis has been a largely ineffectual compromise (for reviews see refs [1] [2] [3] [4] [5] [6] . Recent investigations of the microstructure and histomorphometry of this form of osteoporosis and advances in new forms of treatment now provide a more logical basis for its management."C ushing's disease and corticosteroid osteoporosis The osteoporosis of endogenous Cushing's disease closely resembles that due to exogenous corticosteroids and, although there are differences in the clinical and endocrine environment,'0 the study of one provides lessons for the other. There are many indications for corticosteroid treatment; for instance, to subdue the short term illness of sensitivity reactions; to avert catastrophe, as in the potential blindness of temporal arteritis; and to provide long term control of chronic diseases where alternative treatments prove to be ineffective (as in asthma and rheumatoid arthritis). Although bone loss may rapidly develop in patients given large doses of corticosteroids for a short time, prolonged treatment is the most frequent cause of bone problems. Patients who develop corticosteroid osteoporosis may have an underlying condition which itself predisposes to bone loss, such as rheumatoid arthritis or Crohn's disease; or the skeleton may be unharmed before corticosteroids are given, as in chronic respiratory disease. The skeletal effects of corticosteroids will be influenced by the patient's age, which determines pretreatment bone mass and potential reversibility. The growing skeleton may be severely affected by corticosteroid excess but this is reversible, whereas in the elderly the effects of corticosteroids are imposed on pre-existing involutional osteoporosis and this is not in practice reversible.
Against this clinical background the clinician will want to know how corticosteroids act on the skeleton, the clinical consequences of these effects, whether there is a threshold dose below which the bone is unaffected, and the measures that can be taken to try to prevent or treat bone loss.
Effects of corticosteroids on the skeleton PHYSIOLOGY Much of the experimental work on the skeletal effects of corticosteroids is contradictory.6 Single and mixed populations of cells in culture and in tissues respond differently, as do different animal species, the result being a very opaque view of the effects in man (reviewed in ref 11) . In physiological amounts cortisol exerts a permissive effect on many cellular and hormonal functions via the ubiquitous glucocorticoid receptor. At higher, non-physiological concentrations corticosteroids directly and profoundly suppress the activities of the osteoblast and the differentiation of its progenitor cells (figure). The effects of corticosteroids on osteoclasts are controversial, but are probably mediated through osteoblasts to increase bone resorption. Corticosteroids also directly block calcium transport through the enterocytes, independently of any effect on the metabolism or actions of vitamin D, and they have a minor suppressive effect on the renal reabsorption of calcium, causing hypercalcuria. In addition to these direct effects, corticosteroids have indirect effects on the skeleton through their influence on the actions of other hormones. When given initially corticosteroids increase the activity of parathyroid hormone, probably as a result of reduced intestinal transport and increased renal loss of calcium; and there is also evidence that they potentiate the activity of parathyroid hormone on osteoblasts (and through them the osteoclasts). Corticosteroids are also likely to have important effects on local cellular messengers within bone, such as the cytokines, and on growth factors. Finally, corticosteroids have a complex effect on sex hormone secretion; in addition to suppression of pituitary gonadotrophins there is evidence of direct suppressive effects on the ovary and testes, and of reduced production of adrenal androstenedione. The important reduction in sex hormones contributes to further loss of bone from the skeleton. Although the effects of corticosteroids are complex and in some areas the evidence is confused (see refs 4-6), suppression of new bone formation appears to be a major reason for corticosteroid osteoporosis. Biochemically the degree of this suppression is well indicated by reduced plasma concentrations of osteocalcin, a major osteoblast product,'2 and anatomically by widespread thinning of the bony trabeculae.
MICROSTRUCTURE AND HISTOMORPHOMETRY
Normal bone is constantly being removed by osteoclasts and replaced by osteoblasts. These closely linked functions occur in coordinated cellular groups or remodelling units (basic multicellular units). The timing of the different activities within bone remodelling cycles is known approximately.'3 Activation of a remodelling unit leads to bone resorption (which is initially osteoclastic and continues for two to three weeks). This resorption is followed by a phase of reversal (about nine days) followed by osteoblastic new bone formation (about two weeks) and subsequently mineralisation (130 days). The total period of a remodelling cycle in a normal adult is about 200 days. This is followed by a very variable period of quiescence, which may last from weeks to years. Against this background, bone loss occurs because of an imbalance between resorption and formation that favours resorption. Such imbalance can clearly result from reduced formation, increased resorption, or both, and has its first major but not exclusive effect on trabecular bone. Trabecular bone has a There is increasing evidence that appropriate exercise can prevent bone loss and in some instances increase bone mass by increasing new bone formation and preventing its resorption. Appropriate advice may be difficult to follow, especially where there is painful vertebral collapse or severe underlying illness. The usefulness of exercise in corticosteroid osteoporosis is not formally established.
In contrast, there is no doubt that oral sodium fluoride stimulates the formation of new bone matrix, which can be mineralised provided that adequate calcium and (according to some) vitamin D are given. Radiological vertebral bone density increases, and early studies suggested a decrease in the rate of vertebral fracture. Recent double blind placebo controlled trials have not confirmed this, however, and there are now serious reservations about the use of fluoride.25 These reservations arise not only from the apparent ineffectiveness of fluoride in preventing vertebral fractures but also from the high incidence of side effects. These affect the gastrointestinal tract and the skeleton, causing a painful lower extremity syndrome with increased isotope uptake in the affected areas (particularly the lower tibial metaphyses), which may indicate stress fractures; there is also some evidence that femoral neck fractures may be increased in patients treated with fluoride. Consequently, although limited histological studies suggest that the effects of corticosteroids on bone remodelling can be reversed by using fluoride, and have shown a substantial increase in trabecular bone volume,26 the side effects must be regarded as prohibitive.
Limited short term studies have investigated the effects of anabolic steroids in postmenopausal women with corticosteroid osteoporosis. Nandrolone has been shown to be beneficial but the use of such agents in women is limited by their virilising side effects. Serum testosterone concentrations are reduced in men treated with glucocorticoids and hormone replacement therapy should be beneficial. In women testosterone is given with oestrogen in the form of subcutaneous implants (see below). Whether the testosterone in these implants contributes to the recorded increase in bone density that occurs is not clear.
SUPPRESSION OF BONE RESORPTION
The ways in which bone resorption may be inhibited include relatively simple measures such as giving oral calcium and vitamin D to increase intestinal calcium absorption (and hence, by increasing plasma calcium, reduce parathormone mediated resorption); direct suppression of the osteoclast by the use of either calcitonin or bisphosphonate (particularly pamidronate); and in women hormone replacement therapy (which may also have a direct effect on the osteoblasts). Again the evidence for the usefulness of these forms of treatment in corticosteroid osteoporosis is usually restricted to studies lasting a year or less. Although all show the increase in bone mass expected from the known physiology of bone over this period, long term benefits in corticosteroid osteoporosis have yet to be proved.
Although the reduced absorption of calcium produced by corticosteroids appears to bypass any effect on vitamin D, there is some evidence that giving 25-hydroxyvitamin D (in an average daily dose of 40 gg) with 500 mg of calcium can reduce osteoclast numbers after 12 months and increase metaphyseal and diaphyseal radial bone mass. These changes are associated with improved calcium absorption and a fall in serum parathormone concentrations." Similar short term studies with la-hydroxycholecalciferol or 1,25-dihydroxycholecalciferol showed a reduction in cancellous osteoclast surface, without any change in forearm bone mass. Thus, although 25-hydroxyvitamin D taken with calcium rather than calcium alone may confer some benefit, the evidence for this is not convincing,6 and the potential toxicity of vitamin D and its metabolites cannot be disregarded.
The evidence that calcium on its own has a beneficial effect on corticosteroid induced osteoporosis is also fragmentary. Certainly oral calcium increases the amount absorbed and decreases bone resorption, as assessed by urinary total hydroxyproline excretion; but this is not a particular feature of steroid induced osteoporosis. As in other forms of osteoporosis, there is no consistent or long term evidence that giving additional calcium alone significantly reduces the rate of bone loss.
Calcitonin rapidly inhibits bone resorption by the osteoclast and is therefore a potentially useful agent in preventing bone loss. Its effects are only temporary, however, it has considerable side effects, and it is expensive; and until recently it had to be given by injection. Now that apparently effective intranasal preparations are available its effects in corticosteroid induced osteoporosis are likely to be investigated further.
In contrast, the new bisphosphonates, particularly 3-amino-1-hydroxypropylidene-1,1-bisphosphonate (APD; pamidronate) are effective orally and have no appreciable side effects. They have been shown to reduce both resorption and formation of bone, and to produce a sustained increase in the bone mineral density ofpatients with steroid induced osteoporosis for up to two years.27 28 In perimenopausal or postmenopausal women with corticosteroid induced osteoporosis treatment with oestrogen (and progestogen unless a hysterectomy has been performed) would seem logical for preventing continuing bone resorption. A case could also be made for hormone replacement therapy in the earlier years as such patients are deficient in adrenal derived oestrogen. This has led to some controversy, however, and it has been suggested that the proved effectiveness of percutaneous hormone implants (containing both oestrogen and testosterone) is due to the anabolic effects of testosterone rather than any effect of oestrogen.29 Nevertheless, in six patients with corticosteroid osteoporosis who received such implants there was an increase in vertebral bone density of 1255% and of proximal femoral density of 7 50 in one year. Oestrogen may have an anabolic effect, stimulating collagen synthesis, as well as its antiresorptive action. 30 Finally, the use of thiazide diuretics should be mentioned. These agents reduce the urinary excretion of calcium by increasing its renal tubular reabsorption and have been shown to slow postmenopausal bone loss. Patients taking thiazides also have a reduced rate of femoral neck fracture.3' One way in which thiazides could prevent bone loss is by conserving calcium and reducing bone resorption. As one of the minor effects of glucocorticoids is to produce hypercalcuria thiazide treatment would seem very logical in corticosteroid osteoporosis, but long term studies of bone density have yet to be done.
COMBINED REGIMENS
Clearly anabolic and antiresorptive regimens can be combined. This has been done in an apparently haphazard manner-for instance, the anabolic steroid nandrolone has been given with oral calcium in the form ofmicrocrystalline hydroxyapatite to produce an appreciable increase in total body calcium in the first year and a temporary increase in osteocalcin."2 Cyclical treatment may be more logical and attempts have been made to manipulate the remodelling cycles by alternating periods of cellular activation (A) with periods of cellular depression (D) and with periods free of treatment (F) and using repeated cycles (R)-an ADFR regimen. A regimen using phosphate as an activator and etidronate as a depressor has been used cyclically in the treatment of postmenopausal osteoporosis. ADFR regimens have been investigated for only a short time and all results must be regarded as preliminary. The time for which these cycles are given is variable and depressors such as etidronate may be used intermittently on their own.
Practical issues
How far does this knowledge of corticosteroid induced osteoporosis help the clinician? It provides an insight into the multiple effects of corticosteroids on the bone and its cells, and some understanding of how corticosteroid osteoporosis differs from other forms such as involutional osteoporosis. There does not appear to be a well defined threshold dose of corticosteroids, and recovery from corticosteroid osteoporosis appears to be most likely in young people, especially where there is potential for growth. It should be possible to put the management of corticosteroid induced bone loss on a more logical basis.
There are three important practical questions to which only partial answers can be given. The first is whether the amount of corticosteroid induced bone loss can be predicted (who will lose bone, and how much and how fast?). Secondly, how long can corticosteroids be given without ill effect? Thirdly, what practical therapeutic measures can be taken to prevent corticosteroid induced osteoporosis?
The first two questions are interrelated. Although there appears to be considerable variation in the susceptibility of the skeleton to corticosteroids, in general the amount of bone loss is related to the total amount of corticosteroids given, and the loss is greatest with a high total dose that is, a high daily dose, prolonged treatment, or both. As the likelihood of fracture is broadly related to the amount of bone (the bone mineral density) is it important to measure bone density before starting corticosteroid treatment? Where a bone densitometer is available, preferably a dual x ray (DEXA) machine capable of measuring spinal bone density, the answer must be yes, as it will provide a pretreatment measurement of bone mass (which may be excessively low, as in an elderly woman), and when the measurement is repeated it will give an indication of the rate of bone loss with the patient taking corticosteroids. Unfortunately instruments capable of measuring spinal bone density are not widely available. Measurement of forearm bone density with a single isotope source provides an economic alternative that is better than having no measurement at all, especially when serial readings are made; but because corticosteroid osteoporosis preferentially affects trabecular bone and the vertebrae it provides a less sensitive measure. As Lukert and Raisz6 point out, some patients taking glucocorticoids do not develop osteoporosis so it is important to identify those at risk to assess the effectiveness of prevention. They consider that patients most likely to develop osteoporosis (without reference to the amount of corticosteroids) have the lowest initial bone mass and muscle strength (because of the association between corticosteroid osteoporosis and myopathy) and, during corticosteroid treatment, the most serious impairment of calcium absorption, the highest urinary loss of calcium, the greatest degree of secondary hyperparathyroidism, and the most dramatic inhibitory effect of corticosteroids on their osteoblastic function. In practice this implies that, apart from normal physical examination, the initial assessment and subsequent follow up of patients taking corticosteroids should include measurement of spinal bone density, urine calcium, plasma parathormone, and osteocalcin. In addition, vitamin D deficiency should also be excluded by measuring plasma 25-hydroxyvitamin D because deficiency appears to augment the deleterious effects of corticosteroids.
The answer to the second question is that corticosteroid treatment should be given for the shortest time compatible with control of the illness for which it is prescribed. Clearly the decision will depend very much on the disorder and the individual. Giant cell arteritis and temporal arteritis provide a useful example." Both are self limiting disorders, so there is a risk of continuing corticosteroids unnecessarily. From one fifth to a half of those treated have serious side effects unless the initial dose of prednisolone is 10 mg or less and the maintenance dose less than 7-5 mg. There appears to be no reliable way of telling which patients are at risk from side effects, apart from the clear relation to total dose. The authors conclude that treatment should normally continue for at least two years and that relapse should be monitored every six months thereafter. They advise using azathioprine as it has a modest corticosteroid sparing effect and reducing prednisolone to alternate day administration once the daily dose is less than 5 mg to make eventual drug withdrawal easier.
In answer to the third question, the practical (as opposed to the theoretical) therapeutic alternatives are limited. On the whole, physicians do not like to counteract the effects of one powerful drug with those ofanother. At present the use of injectable calcitonin and oral sodium fluoride, both of which have appreciable side effects, is not recommended. Nasal calcitonin remains a possibility for the future, as do phosphonates such as disodium etidronate (Didronel, EHDP) and pamidronate. It is sensible to recommend exercise and additional oral calcium, which have well tried but undramatic effects in preventing bone loss, for preventing corticosteroid osteoporosis. 
